Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

Inclusion Criteria: * Patients of both sexes aged 35 to 75 years inclusive. * Diagnosis of primary open-angle glaucoma stage II or III in both eyes. * Intraocular pressure (IOP) compliance with ""target level"": tonometric IOP \<21 mmHg in stage II, \<19 mmHg in stage III, in both eyes. * The patient's willingness and ability to fulfil the requirements of the protocol throughout the trial. * Patients who signed informed consent to participate in the trial. * For women with preserved reproductive potential, a negative pregnancy test and agreement to use adequate contraceptive methods throughout the trial. * For men, agreement to adhere to adequate contraceptive methods for the duration of trial participation. Exclusion Criteria: * Individual intolerance or hypersensitivity to any of the components of the investigational medicinal products according to anamnesis data. * Administration of nootropic, vasoactive drugs, neuroprotectants, antioxidants, metabolic drugs for 30 days prior to randomisation. * The need to use medications that are prohibited in this trial. * Primary open-angle glaucoma stage I or IV in at least one eye. * Closed-angle glaucoma of at least one eye. * The only eye. * Diagnosis of primary open-angle glaucoma stage II or III in one eye only. * Visual acuity less than 0.1 (with correction) in at least one eye. * Presence of an active infectious-inflammatory process in at least one eye. * Low reliability of SAP results in at least one eye due to the patient'…